Article

CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphoma

2026-02-17

Abstract excerpt

<title>Abstract</title> <p>More than half of patients with relapsed/refractory large B-cell lymphoma experience disease progression after CD19-directed chimeric antigen receptor (CAR19) T-cell therapy. We investigated CAR22 therapy in 38 patients with CAR19-refractory disease, achieving 68% overall response rate (ORR) and 53% complete response rate (CR)(NCT04088890). Long-term follow-up (median 43.5 months), reve...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 26d494f1-3464-5444-82ad-b1407bde8696
DOI: 10.21203/rs.3.rs-7706791/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphomaDOI 10.21203/rs.3.rs-7706791/v1Read

Genomic drivers of large B-cell lymphoma resistance to CD19 CAR-T therapySemantic proximity Read

Distinct cellular dynamics associated with response to CAR-T therapy for refractory B-cell lymphomaSemantic proximity Read

Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphomaSemantic proximity Read

Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma PatientsSemantic proximity Read

CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopeniasSemantic proximity Read

Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.Semantic proximity Read

Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin LymphomaSemantic proximity Read

Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasiasSemantic proximity Read

<i>RHOA</i> Deletion Downregulates CD19 and Promotes Dysfunctional Immune Microenvironments in CAR-T Resistant B-Cell LymphomaSemantic proximity Read

Single-Cell Analysis Reveals Ide-cel and Cilta-cel Characteristics That Influence EfficacySemantic proximity Read

Characteristics of premanufacture CD8+ T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphomaSemantic proximity Read

Lenalidomide enhances CD19 CAR-T cell fitness and target-cell engagement in relapsed/refractory CLLSemantic proximity Read